{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:36:53Z","timestamp":1787063813698,"version":"build-2736575974"},"reference-count":98,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective::<\/jats:title>\n                    <jats:p>Pharmacotherapy is commonly used during quit attempts Abstract: and has shown an\nincrease in the likelihood of achieving abstinence. However, with established pharmacotherapies,\nabstinence rates following a quit attempt remain low, and relapse is common. This review aims to\ninvestigate the efficacy and harm profiles of current and emerging pharmacotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods::<\/jats:title>\n                    <jats:p>Literature review of current and emerging pharmacotherapies for smoking cessation and\ntobacco use disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results::<\/jats:title>\n                    <jats:p>Emerging pharmacotherapies include new formulations of existing therapies, drug repurposing\nand some new treatments. New treatments are welcome and may incorporate different\nmechanisms of action or different safety and tolerability profiles compared to existing treatments.\nHowever, emerging pharmacotherapies have yet to demonstrate greater efficacy compared to existing\ntreatments. The emergence of Electronic Nicotine Delivery Systems (ENDS) or \u2018vaping\u2019 is a\nfeature of the current debate around tobacco use disorder. ENDS appear to facilitate switching but\nnot quitting and are controversial as a harm minimisation strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations::<\/jats:title>\n                    <jats:p>Studies included a broad range of therapies and trial designs that should be compared\nwith their differences taken into consideration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion::<\/jats:title>\n                    <jats:p>Strategies to successfully quit smoking vary between individuals and may extend beyond\npharmacotherapy and involve complex psychosocial factors and pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127724328274939231121114142","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T04:57:12Z","timestamp":1703653032000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Pharmacotherapies for Smoking Cessation and Promising\nEmerging Drugs"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-4636","authenticated-orcid":true,"given":"Seetal","family":"Dodd","sequence":"first","affiliation":[{"name":"IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University,\nBarwon Health, P.O. Box 281, Geelong, 3220, Australia"},{"name":"Orygen, The National Centre of Excellence in Youth\nMental Health, the Department of Psychiatry, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Harper","sequence":"additional","affiliation":[{"name":"School of Medicine,\nDeakin University, Geelong, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University,\nBarwon Health, P.O. Box 281, Geelong, 3220, Australia"},{"name":"Orygen, The National Centre of Excellence in Youth\nMental Health, the Department of Psychiatry, The University of Melbourne, Parkville, Australia"},{"name":"Florey Institute of Neuroscience and Mental Health, The University of Melbourne,\nParkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/bmj.327.7407.154","volume":"327","author":"Shibuya K.","year":"2003","unstructured":"Shibuya K.; Ciecierski C.; Guindon E.; Bettcher D.W.; Evans D.B.; Murray C.J.; WHO Framework Convention on Tobacco Control: Development of an evidence based global public health treaty. BMJ  2003,327(7407),154-157","journal-title":"BMJ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1055-9965.EPI-13-0798","volume":"23","author":"Cummings K.M.","year":"2014","unstructured":"Cummings K.M.; Proctor R.N.; The changing public image of smoking in the United States: 1964-2014. Cancer Epidemiol Biomarkers Prev  2014,23(1),32-36","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=3","author":"Greenhalgh E.M.","year":"2020","unstructured":"Greenhalgh E.M.; 7.2 Quitting activity. In Greenhalgh, EM, Scollo, MM and Winstanley, MH [Eds]: Tobacco in Australia: facts and issues.  Available from:  http:\/\/www.tobaccoinaustralia.org.au\/chapter-7-cessation\/7-2-quitting-activity2020"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.addbeh.2008.11.013","volume":"34","author":"Zhou X.","year":"2009","unstructured":"Zhou X.; Nonnemaker J.; Sherrill B.; Gilsenan A.W.; Coste F.; West R.; Attempts to quit smoking and relapse: Factors associated with success or failure from the ATTEMPT cohort study. Addict Behav  2009,34(4),365-373","journal-title":"Addict Behav"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"160600","DOI":"10.5888\/pcd14.160600","volume":"14","author":"Caraballo R.S.","year":"2017","unstructured":"Caraballo R.S.; Shafer P.R.; Patel D.; Davis K.C.; McAfee T.A.; Quit methods used by US adult cigarette smokers, 2014\u20132016. Prev Chronic Dis  2017,14,160600","journal-title":"Prev Chronic Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.addbeh.2011.07.024","volume":"36","author":"Brown A.E.","year":"2011","unstructured":"Brown A.E.; Carpenter M.J.; Sutfin E.L.; Occasional smoking in college: Who, what, when and why? Addict Behav  2011,36(12),1199-1204","journal-title":"Addict Behav"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1007\/s12035-019-1635-x","volume":"56","author":"Wilar G.","year":"2019","unstructured":"Wilar G.; Shinoda Y.; Sasaoka T.; Fukunaga K.; Crucial Role of Dopamine D2 receptor signaling in nicotine-induced conditioned place preference. Mol Neurobiol  2019,56(12),7911-7928","journal-title":"Mol Neurobiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3831\/KPI.2020.23.001","volume":"23","author":"Tiwari R.K.","year":"2020","unstructured":"Tiwari R.K.; Sharma V.; Pandey R.K.; Shukla S.S.; Nicotine addiction: Neurobiology and mechanism. J Pharmacopuncture  2020,23(1),1-7","journal-title":"J Pharmacopuncture"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.bcp.2009.06.011","volume":"78","author":"Govind A.P.","year":"2009","unstructured":"Govind A.P.; Vezina P.; Green W.N.; Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol  2009,78(7),756-765","journal-title":"Biochem Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.pharmtox.48.113006.094742","volume":"49","author":"Benowitz N.L.","year":"2009","unstructured":"Benowitz N.L.; Pharmacology of nicotine: Addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol  2009,49(1),57-71","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bcp.2009.06.004","volume":"78","author":"Livingstone P.D.","year":"2009","unstructured":"Livingstone P.D.; Wonnacott S.; Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol  2009,78(7),744-755","journal-title":"Biochem Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"CD000146","DOI":"10.1002\/14651858.CD000146.pub5","volume":"2019","author":"Hartmann-Boyce J.","year":"2018","unstructured":"Hartmann-Boyce J.; Chepkin S.C.; Ye W.; Bullen C.; Lancaster T.; Nicotine replacement therapy versus control for smoking cessation. Cochrane Libr  2018,2019(1),CD000146","journal-title":"Cochrane Libr"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1753-6405.2011.00733.x","volume":"35","author":"Cooper J.","year":"2011","unstructured":"Cooper J.; Borland R.; Yong H.H.; Australian smokers increasingly use help to quit, but number of attempts remains stable: Findings from the International Tobacco Control Study 2002\u201309. Aust N Z J Public Health  2011,35(4),368-376","journal-title":"Aust N Z J Public Health"},{"key":"ref=14","first-page":"CD000146","volume":"11","author":"Stead L.F.","year":"2012","unstructured":"Stead L.F.; Perera R.; Bullen C.; Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev  2012,11,CD000146","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"110223","DOI":"10.1016\/j.forsciint.2020.110223","volume":"309","author":"Tjoncke J-A.","year":"2020","unstructured":"Tjoncke J-A.; Goncalves R.; Castaing N.; Molimard M.; Tovagliaro F.; Titier K.; Death related to nicotine replacement therapy: A case report. Forensic Sci Int  2020,309,110223","journal-title":"Forensic Sci Int"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"CD010078","DOI":"10.1002\/14651858.CD010078.pub3","volume":"2020","author":"Claire R.","year":"2020","unstructured":"Claire R.; Chamberlain C.; Davey M.A.; Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Libr  2020,2020(3),CD010078","journal-title":"Cochrane Libr"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.12816\/0048737","volume":"10","author":"Wadgave U.","year":"2016","unstructured":"Wadgave U.; Nagesh L.; Nicotine replacement therapy: An overview. Int J Health Sci  2016,10(3),407-416","journal-title":"Int J Health Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/j.1360-0443.2010.02989.x","volume":"105","author":"Bullen C.","year":"2010","unstructured":"Bullen C.; Howe C.; Lin R.B.; Pre-cessation nicotine replacement therapy: Pragmatic randomized trial. Addiction  2010,105(8),1474-1483","journal-title":"Addiction"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1360-0443.2008.02138.x","volume":"103","author":"Shiffman S.","year":"2008","unstructured":"Shiffman S.; Ferguson S.G.; Nicotine patch therapy prior to quitting smoking: A meta-analysis. Addiction  2008,103(4),557-563","journal-title":"Addiction"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"CD013308","DOI":"10.1002\/14651858.CD013308","volume":"2019","author":"Lindson N.","year":"2019","unstructured":"Lindson N.; Chepkin S.C.; Ye W.; Fanshawe T.R.; Bullen C.; Hartmann-Boyce J.; Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Libr  2019,2019(4),CD013308","journal-title":"Cochrane Libr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3322\/canjclin.55.5.281","volume":"55","author":"Henningfield J.E.","year":"2005","unstructured":"Henningfield J.E.; Fant R.V.; Buchhalter A.R.; Stitzer M.L.; Pharmacotherapy for nicotine dependence. CA Cancer J Clin  2005,55(5),281-299","journal-title":"CA Cancer J Clin"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00213-011-2204-9","volume":"216","author":"Shahab L.","year":"2011","unstructured":"Shahab L.; McEwen A.; West R.; Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: A randomised crossover trial. Psychopharmacology  2011,216(2),187-196","journal-title":"Psychopharmacology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.amepre.2016.10.036","volume":"52","author":"Glasser A.M.","year":"2017","unstructured":"Glasser A.M.; Collins L.; Pearson J.L.; Overview of electronic nicotine delivery systems: A systematic review. Am J Prev Med  2017,52(2),e33-e66","journal-title":"Am J Prev Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(13)61842-5","volume":"382","author":"Bullen C.","year":"2013","unstructured":"Bullen C.; Howe C.; Laugesen M.; Electronic cigarettes for smoking cessation: A randomised controlled trial. Lancet  2013,382(9905),1629-1637","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1808779","volume":"380","author":"Hajek P.","year":"2019","unstructured":"Hajek P.; Phillips-Waller A.; Przulj D.; A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med  2019,380(7),629-637","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"L585","DOI":"10.1152\/ajplung.00160.2020","volume":"319","author":"McAlinden K.D.","year":"2020","unstructured":"McAlinden K.D.; Eapen M.S.; Lu W.; Sharma P.; Sohal S.S.; The rise of electronic nicotine delivery systems and the emergence of electronic-cigarette-driven disease. Am J Physiol Lung Cell Mol Physiol  2020,319(4),L585-L595","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.15585\/mmwr.mm6903e2","volume":"69","author":"Krishnasamy VP","year":"2020","unstructured":"Krishnasamy VP; Hallowell BD; Ko JY; Update: Characteristics of a nationwide outbreak of E-cigarette, or vaping, product use\u2013associated lung injury \u2014 united states, august 2019\u2013january 2020. mmwr morb Mortal Wkly Rep  2020,69(3),90-4"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jamapediatrics.2017.1488","volume":"171","author":"Soneji S.","year":"2017","unstructured":"Soneji S.; Barrington-Trimis J.L.; Wills T.A.; Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults. JAMA Pediatr  2017,171(8),788-797","journal-title":"JAMA Pediatr"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s11739-019-02228-8","volume":"15","author":"Polosa R.","year":"2020","unstructured":"Polosa R.; Farsalinos K.; Prisco D.; A double-edged sword: E-cigarettes, and other electronic nicotine delivery systems (ENDS). reply Intern Emerg Med  2020,15(6),1119-1121","journal-title":"Intern Emerg Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s11739-019-02203-3","volume":"15","author":"Sahu K.K.","year":"2020","unstructured":"Sahu K.K.; Mishra A.K.; Lal A.; Abraham G.; A double-edged sword: E-cigarettes, and other electronic nicotine delivery systems (ENDS). Intern Emerg Med  2020,15(6),1117-1118","journal-title":"Intern Emerg Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/tobaccocontrol-2015-052783","volume":"26","author":"Carpenter M.J.","year":"2017","unstructured":"Carpenter M.J.; Wahlquist A.E.; Burris J.L.; Snus undermines quit attempts but not abstinence: A randomised clinical trial among US smokers. Tob Control  2017,26(2),202-209","journal-title":"Tob Control"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2174\/187152711799219343","volume":"10","author":"Fahim R.E.","year":"2011","unstructured":"Fahim R.E.; Kessler P.D.; Fuller S.A.; Kalnik M.W.; Nicotine vaccines. CNS Neurol Disord Drug Targets  2011,10(8),905-915","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=33","first-page":"CD007072","volume":"2012","author":"Hartmann-Boyce J.","year":"2012","unstructured":"Hartmann-Boyce J.; Cahill K.; Hatsukami D.; Cornuz J.; Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev  2012,2012(8),CD007072","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=34","author":"Mukhin A.","unstructured":"Mukhin A.;  Improving the efficacy of anti-nicotine immunotherapy (petnic002).   clinicaltrials.gov identifier. NCT01280968 2014."},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e0254247","DOI":"10.1371\/journal.pone.0254247","volume":"16","author":"Raleigh M.D.","year":"2021","unstructured":"Raleigh M.D.; Beltraminelli N.; Fallot S.; Attenuating nicotine\u2019s effects with high affinity human anti-nicotine monoclonal antibodies. PLoS One  2021,16(7),e0254247","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12896-018-0457-7","volume":"18","author":"Pentel P.R.","year":"2018","unstructured":"Pentel P.R.; Raleigh M.D.; LeSage M.G.; The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats. BMC Biotechnol  2018,18(1),46","journal-title":"BMC Biotechnol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/add.14208","volume":"113","author":"West R.","year":"2018","unstructured":"West R.; Evins A.E.; Benowitz N.L.; Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction  2018,113(8),1507-1516","journal-title":"Addiction"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12916-016-0626-2","volume":"14","author":"Tulloch H.E.","year":"2016","unstructured":"Tulloch H.E.; Pipe A.L.; Els C.; Clyde M.J.; Reid R.D.; Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: A randomized controlled trial. BMC Med  2016,14(1),80","journal-title":"BMC Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/JCP.0000000000001015","volume":"39","author":"Evins A.E.","year":"2019","unstructured":"Evins A.E.; Benowitz N.L.; West R.; Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES Trial. J Clin Psychopharmacol  2019,39(2),108-116","journal-title":"J Clin Psychopharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ntr\/nty055","volume":"21","author":"Turner E.","year":"2019","unstructured":"Turner E.; Jones M.; Vaz L.R.; Coleman T.; Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. Nicotine Tob Res  2019,21(8),1001-1010","journal-title":"Nicotine Tob Res"},{"key":"ref=41","year":"2018","unstructured":"Drug Safety Communication Available from:  https:\/\/ www.fda.gov\/drugs\/drug-safety-and-availability fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking2018"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","volume":"51","author":"Costa R.","year":"2019","unstructured":"Costa R.; Oliveira N.G.; Dinis-Oliveira R.J.; Pharmacokinetic and pharmacodynamic of bupropion: Integrative overview of relevant clinical and forensic aspects. Drug Metab Rev  2019,51(3),293-313","journal-title":"Drug Metab Rev"},{"key":"ref=43","year":"2003","unstructured":"Drug Approval Package US Food and Drug Administration Available from:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/ nda\/97\/020711_zyban_toc.cfm2003","journal-title":"Drug Approval Package"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJM199710233371703","volume":"337","author":"Hurt R.D.","year":"1997","unstructured":"Hurt R.D.; Sachs D.P.L.; Glover E.D.; A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med  1997,337(17),1195-1202","journal-title":"N Engl J Med"},{"key":"ref=45","first-page":"CD000031","volume":"2014","author":"Hughes J.R.","year":"2014","unstructured":"Hughes J.R.; Stead L.F.; Hartmann-Boyce J.; Cahill K.; Lancaster T.; Antidepressants for smoking cessation. Cochrane Database Syst Rev  2014,2014(1),CD000031","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=46","first-page":"CD000031","volume":"4","author":"Howes S.","year":"2020","unstructured":"Howes S.; Hartmann-Boyce J.; Livingstone-Banks J.; Hong B.; Lindson N.; Antidepressants for smoking cessation. Cochrane Database Syst Rev  2020,4(4),CD000031","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/01.crd.0000260270.12829.45","volume":"15","author":"Lam S.","year":"2007","unstructured":"Lam S.; Patel P.N.; Varenicline: A selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev  2007,15(3),154-161","journal-title":"Cardiol Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1124\/mol.106.025130","volume":"70","author":"Mihalak K.B.","year":"2006","unstructured":"Mihalak K.B.; Carroll F.I.; Luetje C.W.; Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol  2006,70(3),801-805","journal-title":"Mol Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.clinthera.2009.03.021","volume":"31","author":"Garrison G.D.","year":"2009","unstructured":"Garrison G.D.; Dugan S.E.; Varenicline: A first-line treatment option for smoking cessation. Clin Ther  2009,31(3),463-491","journal-title":"Clin Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.280","volume":"313","author":"Ebbert J.O.","year":"2015","unstructured":"Ebbert J.O.; Hughes J.R.; West R.J.; Effect of varenicline on smoking cessation through smoking reduction: A randomized clinical trial. JAMA  2015,313(7),687-694","journal-title":"JAMA"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/ntr\/ntw123","volume":"18","author":"Ebbert J.O.","year":"2016","unstructured":"Ebbert J.O.; Croghan I.T.; Hurt R.T.; Schroeder D.R.; Hays J.T.; Varenicline for smoking cessation in light smokers. Nicotine Tob Res  2016,18(10),2031-2035","journal-title":"Nicotine Tob Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/clpt.2014.124","volume":"96","author":"Gonzales D.","year":"2014","unstructured":"Gonzales D.; Hajek P.; Pliamm L.; Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: A randomized, placebo-controlled trial. Clin Pharmacol Ther  2014,96(3),390-396","journal-title":"Clin Pharmacol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","volume":"171","author":"Rose J.E.","year":"2014","unstructured":"Rose J.E.; Behm F.M.; Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry  2014,171(11),1199-1205","journal-title":"Am J Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.3390\/ijerph18189465","volume":"18","author":"Li K.","year":"2021","unstructured":"Li K.; Ricker K.; Tsai F.C.; Estimated cancer risks associated with nitrosamine contamination in commonly used medications. Int J Environ Res Public Health  2021,18(18),9465","journal-title":"Int J Environ Res Public Health"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMoa052963","volume":"354","author":"Rush A.J.","year":"2006","unstructured":"Rush A.J.; Trivedi M.H.; Wisniewski S.R.; Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med  2006,354(12),1231-1242","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","volume":"65","author":"Patterson F.","year":"2009","unstructured":"Patterson F.; Jepson C.; Strasser A.A.; Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry  2009,65(2),144-149","journal-title":"Biol Psychiatry"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0006-3223(00)01094-5","volume":"49","author":"Rezvani A.H.","year":"2001","unstructured":"Rezvani A.H.; Levin E.D.; Cognitive effects of nicotine. Biol Psychiatry  2001,49(3),258-267","journal-title":"Biol Psychiatry"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14622200500185298","volume":"7","author":"Hughes J.","year":"2005","unstructured":"Hughes J.; Stead L.; Lancaster T.; Nortriptyline for smoking cessation: A review. Nicotine Tob Res  2005,7(4),491-499","journal-title":"Nicotine Tob Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.drugalcdep.2004.06.004","volume":"76","author":"John U.","year":"2004","unstructured":"John U.; Meyer C.; Rumpf H.J.; Hapke U.; Smoking, nicotine dependence and psychiatric comorbidity\u2014a population-based study including smoking cessation after three years. Drug Alcohol Depend  2004,76(3),287-295","journal-title":"Drug Alcohol Depend"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/ntr\/ntz070","volume":"22","author":"Schlam T.R.","year":"2020","unstructured":"Schlam T.R.; Baker T.B.; Smith S.S.; Cook J.W.; Piper M.E.; Anxiety sensitivity and distress tolerance in smokers: Relations with tobacco dependence, withdrawal, and quitting success. Nicotine Tob Res  2020,22(1),58-65","journal-title":"Nicotine Tob Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/syn.20688","volume":"63","author":"Esterlis I.","year":"2009","unstructured":"Esterlis I.; Cosgrove K.P.; Batis J.C.; GABA A -benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse  2009,63(12),1089-1099","journal-title":"Synapse"},{"key":"ref=62","first-page":"CD002849","volume":"2000","author":"Hughes J.R.","year":"2000","unstructured":"Hughes J.R.; Stead L.F.; Lancaster T.; Anxiolytics for smoking cessation. Cochrane Database Syst Rev  2000,2000(4),CD002849","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"1461","author":"Loane C.","year":"2012","unstructured":"Loane C.; Politis M.; Buspirone: What is it all about? Brain Res  2012,1461,111-118","journal-title":"Brain Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijms23010042","volume":"23","author":"Wang N.","year":"2021","unstructured":"Wang N.; Lian J.; Cao Y.; High-Dose Benzodiazepines Positively Modulate GABAA receptors via a flumazenil-insensitive mechanism. Int J Mol Sci  2021,23(1),42","journal-title":"Int J Mol Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/AC.65.5.2056244","volume":"65","author":"Gorre F.","year":"2010","unstructured":"Gorre F.; Vandekerckhove H.; Beta-blockers: Focus on mechanism of action Which beta-blocker, when and why? Acta Cardiol  2010,65(5),565-570","journal-title":"Acta Cardiol"},{"key":"ref=66","first-page":"18","author":"Wilson A.T.","year":"2016","unstructured":"Wilson A.T.; The association of benzodiazepine use with smoking cessation among hospitalized smokers in a clinical trial. Clinical Res  2016,18","journal-title":"Clinical Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2146\/ajhp060414","volume":"64","author":"Kroon L.A.","year":"2007","unstructured":"Kroon L.A.; Drug interactions with smoking. Am J Health Syst Pharm  2007,64(18),1917-1921","journal-title":"Am J Health Syst Pharm"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s13063-019-3628-5","volume":"20","author":"Arancini L.","year":"2019","unstructured":"Arancini L.; Bortolasci C.C.; Dodd S.; Dean O.M.; Berk M.; N-acetylcysteine for cessation of tobacco smoking: Rationale and study protocol for a randomised controlled trial. Trials  2019,20(1),555","journal-title":"Trials"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1179\/1351000215Y.0000000004","volume":"20","author":"Prado E.","year":"2015","unstructured":"Prado E.; Maes M.; Piccoli L.G.; N -acetylcysteine for therapy-resistant tobacco use disorder: A pilot study. Redox Rep  2015,20(5),215-222","journal-title":"Redox Rep"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.euroneuro.2021.10.002","volume":"53","author":"Arancini L.","year":"2021","unstructured":"Arancini L.; Mohebbi M.; Berk M.; A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. Eur Neuropsychopharmacol  2021,53,120-126","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1590\/1516-4446-2019-0753","volume":"42","author":"Machado R.C.B.R.","year":"2020","unstructured":"Machado R.C.B.R.; Vargas H.O.; Baracat M.M.; N-acetylcysteine as an adjunctive treatment for smoking cessation: A randomized clinical trial. Br J Psychiatry  2020,42(5),519-526","journal-title":"Br J Psychiatry"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1517\/14728220802517901","volume":"8","author":"Dodd S.","year":"2008","unstructured":"Dodd S.; Dean O.; Copolov D.L.; Malhi G.S.; Berk M.; N -acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert Opin Biol Ther  2008,8(12),1955-1962","journal-title":"Expert Opin Biol Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"282","DOI":"10.9758\/cpn.2021.19.2.282","volume":"19","author":"Chang C.T.","year":"2021","unstructured":"Chang C.T.; Hsieh P.J.; Lee H.C.; Lo C.H.; Tam K.W.; Loh E.W.; Effectiveness of n-acetylcysteine in treating clinical symptoms of substance abuse and dependence: A meta-analysis of randomized controlled trials. Clin Psychopharmacol Neurosci  2021,19(2),282-293","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/03639045.2019.1578787","volume":"45","author":"Moerke M.J.","year":"2019","unstructured":"Moerke M.J.; McMahon L.R.; Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys. Drug Dev Ind Pharm  2019,45(5),861-867","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1038\/tp.2015.209","volume":"6","author":"Ashare R.L.","year":"2016","unstructured":"Ashare R.L.; Kimmey B.A.; Rupprecht L.E.; Bowers M.E.; Hayes M.R.; Schmidt H.D.; Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers. Transl Psychiatry  2016,6(1),e713","journal-title":"Transl Psychiatry"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00213-012-2763-4","volume":"224","author":"Sofuoglu M.","year":"2012","unstructured":"Sofuoglu M.; Herman A.I.; Li Y.; Waters A.J.; Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: A preliminary report. Psychopharmacology  2012,224(3),413-420","journal-title":"Psychopharmacology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"614","DOI":"10.5414\/CPP44614","volume":"44","author":"Diehl A.","year":"2006","unstructured":"Diehl A.; Nakovics H.; Croissant B.; Smolka M.N.; Batra A.; Mann K.; Galantamine reduces smoking in alcohol-dependent patients: A randomized, placebo-controlled trial. Int J Clin Pharmacol Ther  2006,44(12),614-622","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e2665","DOI":"10.1002\/hup.2665","volume":"33","author":"MacLean R.R.","year":"2018","unstructured":"MacLean R.R.; Waters A.J.; Brede E.; Sofuoglu M.; Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. Hum Psychopharmacol  2018,33(4),e2665","journal-title":"Hum Psychopharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/dta.1707","volume":"7","author":"Jeong S.H.","year":"2015","unstructured":"Jeong S.H.; Newcombe D.; Sheridan J.; Tingle M.; Pharmacokinetics of cytisine, an \u03b1 4 \u03b2 2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal  2015,7(6),475-482","journal-title":"Drug Test Anal"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/add.14721","volume":"114","author":"Tutka P.","year":"2019","unstructured":"Tutka P.; Vinnikov D.; Courtney R.J.; Benowitz N.L.; Cytisine for nicotine addiction treatment: A review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction  2019,114(11),1951-1969","journal-title":"Addiction"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archinte.166.15.1553","volume":"166","author":"Etter J.F.","year":"2006","unstructured":"Etter J.F.; Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med  2006,166(15),1553-1559","journal-title":"Arch Intern Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2021.7621","volume":"326","author":"Courtney R.J.","year":"2021","unstructured":"Courtney R.J.; McRobbie H.; Tutka P.; Effect of cytisine vs varenicline on smoking cessation. JAMA  2021,326(1),56-64","journal-title":"JAMA"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jama.2023.10042","volume":"330","author":"Rigotti N.A.","year":"2023","unstructured":"Rigotti N.A.; Benowitz N.L.; Prochaska J.; Cytisinicline for smoking cessation. JAMA  2023,330(2),152-160","journal-title":"JAMA"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neulet.2018.01.022","volume":"668","author":"Rezvani A.H.","year":"2018","unstructured":"Rezvani A.H.; Tizabi Y.; Slade S.; Getachew B.; Levin E.D.; Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats. Neurosci Lett  2018,668,98-102","journal-title":"Neurosci Lett"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.brainresbull.2011.01.013","volume":"84","author":"Yararbas G.","year":"2011","unstructured":"Yararbas G.; Pogun S.; Tamoxifen and mifepriston modulate nicotine induced conditioned place preference in female rats. Brain Res Bull  2011,84(6),425-429","journal-title":"Brain Res Bull"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"172592","DOI":"10.1016\/j.ejphar.2019.172592","volume":"861","author":"Levin E.D.","year":"2019","unstructured":"Levin E.D.; Wells C.; Yao L.; Chronic memantine decreases nicotine self-administration in rats. Eur J Pharmacol  2019,861,172592","journal-title":"Eur J Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00702-006-0570-y","volume":"114","author":"Thuerauf N.","year":"2007","unstructured":"Thuerauf N.; Lunkenheimer J.; Lunkenheimer B.; Memantine fails to facilitate partial cigarette deprivation in smokers \u2013 no role of Memantine in the treatment of nicotine dependency? J Neural Transm (Vienna)  2007,114(3),351-357","journal-title":"J Neural Transm (Vienna)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00213-018-4853-4","volume":"235","author":"Maggio S.E.","year":"2018","unstructured":"Maggio S.E.; Saunders M.A.; Baxter T.A.; Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology  2018,235(5),1439-1453","journal-title":"Psychopharmacology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugalcdep.2008.04.008","volume":"98","author":"Schnoll R.A.","year":"2008","unstructured":"Schnoll R.A.; Wileyto E.P.; Pinto A.; A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend  2008,98(1-2),86-93","journal-title":"Drug Alcohol Depend"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1124\/jpet.107.133900","volume":"324","author":"Siu E.C.K.","year":"2008","unstructured":"Siu E.C.K.; Tyndale R.F.; Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther  2008,324(3),992-999","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/ntr\/ntr143","volume":"14","author":"Kahn R.","year":"2012","unstructured":"Kahn R.; Gorgon L.; Jones K.; Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res  2012,14(3),377-382","journal-title":"Nicotine Tob Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/j.1360-0443.2010.03020.x","volume":"105","author":"Killen J.D.","year":"2010","unstructured":"Killen J.D.; Fortmann S.P.; Murphy G.M.; Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction  2010,105(9),1660-1668","journal-title":"Addiction"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1046\/j.1360-0443.1999.948122713.x","volume":"94","author":"Wong G.Y.","year":"1999","unstructured":"Wong G.Y.; Wolter T.D.; Croghan G.A.; Croghan I.T.; Offord K.P.; Hurt R.D.; A randomized trial of naltrexone for smoking cessation. Addiction  1999,94(8),1227-1237","journal-title":"Addiction"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.addbeh.2007.05.012","volume":"33","author":"Toll B.A.","year":"2008","unstructured":"Toll B.A.; Leary V.; Wu R.; Salovey P.; Meandzija B.; O\u2019Malley S.S.; A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict Behav  2008,33(1),173-179","journal-title":"Addict Behav"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.drugalcdep.2010.04.015","volume":"111","author":"Toll B.A.","year":"2010","unstructured":"Toll B.A.; White M.; Wu R.; Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug Alcohol Depend  2010,111(3),200-206","journal-title":"Drug Alcohol Depend"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000439525","volume":"22","author":"Zaparoli J.X.","year":"2016","unstructured":"Zaparoli J.X.; Sugawara E.K.; de Souza A.A.L.; Tufik S.; Galdur\u00f3z J.C.F.; Omega-3 levels and nicotine dependence: A cross-sectional study and clinical trial. Eur Addict Res  2016,22(3),153-162","journal-title":"Eur Addict Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/1940-6207.CAPR-13-0083","volume":"6","author":"Mohebati A.","year":"2013","unstructured":"Mohebati A.; Milne G.L.; Zhou X.K.; Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res  2013,6(7),646-655","journal-title":"Cancer Prev Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0269881112454228","volume":"26","author":"Laatikainen L.M.","year":"2012","unstructured":"Laatikainen L.M.; Sharp T.; Bannerman D.M.; Harrison P.J.; Tunbridge E.M.; Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. J Psychopharmacol  2012,26(12),1561-1568","journal-title":"J Psychopharmacol"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328274939231121114142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/224808\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328274939231121114142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:10:05Z","timestamp":1712218205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/224808\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328274939231121114142","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}